Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Ming L. Chen"'
Autor:
Sarah K Tasian, Deborah S Hunter, I-Ming L Chen, Richard C Harvey, Andrew J. Carroll, Elizabeth Wagner, Shalini C Reshmi, Michael J Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh
Publikováno v:
Blood. 140:6117-6118
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa794e314c401a86a55ef17d1a311669
https://doi.org/10.1182/blood-2022-164699
https://doi.org/10.1182/blood-2022-164699
Autor:
Qing Zhang, Kenneth J. Kopecky, Thomas R. Chauncey, Era L. Pogosova-Agadjanyan, John E. Godwin, Cheryl L. Willman, Jerald P. Radich, Emily A. Stevens, Frederick R. Appelbaum, Anna Moseley, Min Fang, I-Ming L. Chen, Megan Othus, Isaac C. Jenkins, Harry P. Erba, Soheil Meshinchi, Mike Huynh, Brent L. Wood, Alan F. List, Derek L. Stirewalt, Brooke E. Willborg, Jasmine Naru
Publikováno v:
Biomarker Research, Vol 8, Iss 1, Pp 1-13 (2020)
Biomarker Research
Biomarker Research
Background The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage patients with acute myeloid leukemia for optimal therapies. Despite the identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ede634f4f96fd17750127cbe5842175
http://link.springer.com/article/10.1186/s40364-020-00208-1
http://link.springer.com/article/10.1186/s40364-020-00208-1
Publikováno v:
Journal of Dermatological Treatment. 32:350-354
To systematically explore the risk factors of cutaneous warts and influence factor for the effectiveness of 5-fluorouracil (5-FU).This is a case-control study of 408 cutaneous warts patients and 408 controls of Chinese Han population in southern Chin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9afd080b58231524ad86a4ada4746e8b
https://doi.org/10.1080/09546634.2019.1654073
https://doi.org/10.1080/09546634.2019.1654073
Autor:
Pogosova-Agadjanyan, Era L., Moseley, Anna, Othus, Megan, Appelbaum, Frederick R., Chauncey, Thomas R., I-Ming L. Chen, Erba, Harry P., Godwin, John E., Jenkins, Isaac C., Fang, Min, Huynh, Mike, Kopecky, Kenneth J., List, Alan F., Naru, Jasmine, Radich, Jerald P., Stevens, Emily, Willborg, Brooke E., Willman, Cheryl L., Wood, Brent L., Zhang, Qing, Meshinchi, Soheil, Stirewalt, Derek L.
Additional file 1: Table S1. Targeted Sequencing Details. Table S1A. Target regions for Wafergen Sequencing. Table S1B Primers and Amplicon Details for Wafergen Sequencing. Table S1C. Primers for CEBPA targeted MiSeq Assay. Table S2. Loci that Failed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::243f8711220495b4dd0b9221b05cc944
Autor:
Carolyn A. Felix, Patrizia Porazzi, Joanne M. Hilden, James W Davenport, Sarah K. Tasian, Meenakshi Devidas, ZoAnn E. Dreyer, Shenghao Jin, I-Ming L. Chen, Alix E. Seif, Tiffaney Vincent, Andrew J. Carroll, Martin Carroll, Blaine W. Robinson, Karen A. Urtishak, David T. Teachey, Katherine L. B. Borden, Biljana Culjkovic-Kraljacic, Stephen P. Hunger, Li-San Wang, Jeffrey S. Barrett, Jonni S. Moore, Richard C. Harvey, Nyla A. Heerema, Cheryl L. Willman
Publikováno v:
Oncogene
The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4fb9a36cc87b5cda83511517385570
http://europepmc.org/articles/PMC6440839
http://europepmc.org/articles/PMC6440839
Autor:
Frederick R. Appelbaum, Jerald P. Radich, John E. Godwin, Era L. Pogosova-Agadjanyan, Min Fang, I-Ming L. Chen, Derek L. Stirewalt, Cheryl L. Willman, Alan F. List, Kenneth J. Kopecky, Harry P. Erba, Thomas R. Chauncey, Brent L. Wood, Megan Othus, Anna Moseley, Galina Pogosov, Soheil Meshinchi
Publikováno v:
Biopreservation and Biobanking. 16:42-52
Current prognostic models for acute myeloid leukemia (AML) are inconsistent at predicting clinical outcomes for individual patients. Variability in the quality of specimens utilized for biomarker discovery and validation may contribute to this progno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3484fa96f8f96694d1264e4bd18c43
https://doi.org/10.1089/bio.2017.0079
https://doi.org/10.1089/bio.2017.0079
Autor:
Alejandro Sweet-Cordero, Alex G. Lee, Stephanie M. Smith, Minyoung Youn, Nathan Sumarsono, I-Ming L. Chen, Henrique Bittencourt, Purvesh Khatri, Lara C. Murphy, Michele S. Redell, Hee-Don Chae, Todd A. Alonzo, Elizabeth Spiteri, Kathleen M. Sakamoto, Elizabeth A. Eklund, Min Huang, Kara L. Davis, Michele Donato, Norman J. Lacayo, Nobuko Hijiya, Parveen Abidi, Jairo Matthews, Ilana Galperin, Cecilia Fu, Gary V. Dahl, Jason Gotlib, Steven M. Kornblau, Jason Erdmann, Catherine Aftandilian
Publikováno v:
Blood. 138:1473-1473
Chronic myeloid leukemia (CML) accounts for 2-9% of leukemias in children and adolescents, and occurs with much greater frequency in adults. Compared to adults, children with CML tend to present with higher white blood cell counts and larger spleens,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b11bcd990cbceeb384a639cb0da8224
https://doi.org/10.1182/blood-2021-148701
https://doi.org/10.1182/blood-2021-148701
Autor:
Natalie Delrocco, Mignon L. Loh, Michael Borowitz, Karen R Rabin, Patrick A Zweidler-McKay, Kelly W Maloney, Leonard A. Mattano, Eric C Larsen, Anne L Angiolillo, Reuven J Schore, Michael J. Burke, Wanda L Salzer, Brent L. Wood, Andrew J Carroll, Nyla A. Heerema, Shalini C Reshmi, Julie M Gastier-Foster, Richard C Harvey, I-Ming L Chen, Kathryn G Roberts, Charles G. Mullighan, Cheryl L Willman, Naomi J Winick, William L. Carroll, Stephen P. Hunger, Elizabeth A. Raetz, Meenakshi Devidas, John Kairalla
Publikováno v:
Blood. 138:2382-2382
Contemporary risk stratification algorithms commonly use threshold-defined categories of clinically relevant risk factors. The Children's Oncology Group (COG) uses National Cancer Institute (NCI) risk group (RG), cytogenetics, and early response to t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd53b5f0fc527765d8446b15dcbad31c
https://doi.org/10.1182/blood-2021-148593
https://doi.org/10.1182/blood-2021-148593
Autor:
Nobuko Hijiya, Gary V. Dahl, Jason Gotlib, Nathan Sumarsono, Alejandro Sweet-Cordero, Henrique Bittencourt, Purvesh Khatri, I-Ming L. Chen, Minyoung Youn, Kathleen M. Sakamoto, Min Huang, Catherine Aftandilian, Elizabeth A. Eklund, Stephanie M. Smith, Norman J. Lacayo, Parveen Abidi, Todd A. Alonzo, Alex G. Lee, Kara L. Davis, Jairo Matthews, Cecilia Fu, Steven M. Kornblau, Hee-Don Chae, Lara C. Murphy, Michele Donato, Michele S. Redell
Publikováno v:
Blood. 136:39-40
Introduction Pediatric chronic myeloid leukemia (CML) accounts for 10-15% of pediatric myeloid leukemias and 2-9% of all pediatric leukemias. There are several unique characteristics of CML diagnosed in children, adolescents, and young adults, compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b86c25f3c17dd51afe9bd55b5afe9fad
https://doi.org/10.1182/blood-2020-142270
https://doi.org/10.1182/blood-2020-142270
Autor:
Eric Larsen, Brent L. Wood, Reuven J. Schore, Shalini C. Reshmi, Kathryn G. Roberts, Nyla A. Heerema, Leonard A. Mattano, Michael J. Borowitz, Wanda L. Salzer, Richard C. Harvey, Elizabeth A. Raetz, John A. Kairalla, Stephen P. Hunger, Cheryl L. Willman, Julie M. Gastier-Foster, Andrew J. Carroll, Meenakshi Devidas, Charles G. Mullighan, Michael J. Burke, Patrick A. Zweidler-McKay, Kelly W. Maloney, Natalie DelRocco, Karen R. Rabin, Anne L. Angiolillo, Mignon L. Loh, Naomi J. Winick, William L. Carroll, I-Ming L. Chen
Publikováno v:
Blood. 136:39-40
Current risk stratification for COG ALL patients (pts) relies on National Cancer Institute (NCI) risk group (RG) at diagnosis, somatic genetics, and early response to therapy as measured by specific thresholds of minimal residual disease (MRD) using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6dd83bdbd6fa22117b09e994ec4c103
https://doi.org/10.1182/blood-2020-139081
https://doi.org/10.1182/blood-2020-139081